BrainStorm Gets FDA Fast-Track Status for ALS Stem Cell Therapy

October 7, 2014

(Reuters) – Israel’s BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration has designated its adult stem cell treatment as a “fast-track” product for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm’s treatment, called NurOwn, is being studied in a mid-stage clinical trial in patients with ALS, also known as Lou Gehrig’s Disease.